Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study.

Manfredi Rizzo, Angelo Maria Patti, Giuseppe Montalto, Manfredi Rizzo, Manisha Chandalia, Nicola Abate, Ali A. Rizvi, Manfredi Rizzo

Risultato della ricerca: Articlepeer review

62 Citazioni (Scopus)

Abstract

Background: Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glycemic properties,but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is stillunknown.Methods: A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history ofcoronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by colordoppler ultrasound.Results: After 8 months, fasting glucose decreased by 2.1 mmol/l and HbA1c by 1.9% (p<0.01 for all). Liraglutidereduced total-cholesterol and triglycerides by 10%, and LDL-cholesterol by 19%, whereas HDL-cholesterol increased by18% (p < 0.01 for all lipid changes). Carotid IMT decreased from 1.19 ± 0.47 to 0.94 ± 0.21 mm (p < 0.01). Yet, changes incarotid IMT did not correlate with changes in any other variable studied.Conclusions: Liraglutide decreases carotid IMT after 8 months treatment independently of its effect on plasma glucoseand lipids concentrations.
Lingua originaleEnglish
pagine (da-a)49-
Numero di pagine5
RivistaCardiovascular Diabetology
Volume13
Stato di pubblicazionePublished - 2014

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Fingerprint Entra nei temi di ricerca di 'Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study.'. Insieme formano una fingerprint unica.

Cita questo